Can-Fite BioPharma Ltd. (CANF)
CANFAMEXBiotechnology: Pharmaceutical Preparations
$1.65
-0.0300 (-1.79%) today
Regular session, Nov 10, 2:03 PM ET
- Market cap
- $4.99m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.64 to $1.69
- 52-week range
- $1.50 to $10.40
- Average volume
- 1.23m
- Previous close
- $1.68
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $8.00, +384.8% from here
Earnings
Next report
Financials
No quarterly figures from the source.
News
8 latest- Can-Fite Highlights Long-Term Outcome From Investigational Liver Cancer Treatment Study RTTNews · 1 day ago
- Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson StudyFintel · 1 day ago
- Can-Fite Presents Final Phase 2a Data For Namodenoson In Pancreatic Cancer RTTNews · Oct 26, 2026
- Can-Fite BioPharma Ltd. Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026Fintel · Oct 26, 2026
- Can-Fite Reports Q2 2026 Results As Liver Cancer Survival Exceeds Expectations RTTNews · Sep 8, 2026
- Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges RTTNews · Sep 2, 2026
- Can-Fite Releases Positive Data For Namodenoson In Treating Pancreatic Cancer RTTNews · Aug 17, 2026
- Can-Fite Advances Phase III Programs; Namodenoson Retains FDA Fast Track Status RTTNews · Aug 12, 2026
The company
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- Region
- Middle East
- Website
- canfite.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.